ABSTRACT
BACKGROUND: The aim of this study was to determine the association between hypertriglyceridemia and hyperuricemia (HUA). METHODS: The study was conducted in 3884 subjects who had not received medication enrolled as a baseline. Each participant received at least three annual health check-ups between 2011 and 2017. The risk of hyperuricemia was assessed in four Quartiles (Q1 to Q4) according to TG levels using multivariate-adjusted logistic regression models. RESULTS: The total incidence rate of HUA was 62.3/1000 person-years. In the univariate analysis, the risk of hyperuricemia in people with hypertriglyceridemia was 2.353 times that of normal triglycerides, with a 95% confidence interval of (2.011, 2.754), and the risk of hyperuricemia in men was 1.86 times of female, and the 95% confidence interval is (1.634, 2.177). After adjusting the potential confounders, the relative risk RR of TG at Q2 Q3 Q4 was 1.445 (95%CI:1.114, 1.901), 2.075 (1.611, 2.674), 2.972 (2.322, 3.804). CONCLUSIONS: TG is an independent risk factor for hyperuricemia. As the level of TG increases, the risk of HUA increases.
Subject(s)
Hypertriglyceridemia/epidemiology , Hyperuricemia/epidemiology , Lipid Metabolism , Triglycerides/blood , Adult , Aged , Female , Humans , Hypertriglyceridemia/blood , Hypertriglyceridemia/pathology , Hyperuricemia/blood , Hyperuricemia/pathology , Male , Middle Aged , Risk Factors , Sex Characteristics , Urban Population , Uric Acid/bloodABSTRACT
Background Clinical evidence indicates that genetic variations may interfere with the mechanism of drug action. Recently, it has been reported that the single nucleotide polymorphisms (SNPs) of STAT4, PTPN2, PSORS1C1 and TRAF3IP2RA genes are associated with the clinical efficacy of tumor necrosis factor (TNF) inhibitors in the treatment of rheumatoid arthritis (RA) patients. Therefore, the detection of the SNPs linked with TNF inhibitor efficacy may provide an important basis for the treatment of RA. This study intended to establish molecular diagnostic methods for genotyping the linked SNPs based on high resolution melting (HRM) curve analysis. Methods The polymerase chain reaction-HRM (PCR-HRM) curve analysis detecting systems were established by designing the primers of the four SNPs, rs7574865G>T, rs7234029A>G, rs2233945C>A and rs33980500C>T, and the performance and clinical applicability of which were evaluated by using the Sanger sequencing method and genotyping test for 208 clinical samples. Results The self-developed molecular diagnostic methods of PCR-HRM were confirmed to be able to correctly genotype the four SNPs, the sensitivity and specificity of which were 100% in this study. The repeatability and reproducibility tests showed that there is little variable in intra-assay and inter-assay (the coefficient of variation ranged from 0.01% to 0.07%). The slight changes of DNA template and primer concentrations, PCR cycle number and reaction system volume had no significant effect on the genotyping performance of the method. The PCR-HRM assays were also applied to other PCR thermocyclers with HRM function and use different saturation fluorescent dyes. Conclusions The PCR-HRM genotyping method established in this study can be applied to the routine molecular diagnosis of rs7574865, rs7234029, rs2233945 and rs33980500.
Subject(s)
Genotyping Techniques , Molecular Diagnostic Techniques , Polymerase Chain Reaction , Polymorphism, Single Nucleotide , Tumor Necrosis Factor Inhibitors , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/genetics , Female , Genotype , Humans , Male , Middle Aged , Pathology, Molecular , Protein Tyrosine Phosphatase, Non-Receptor Type 2/genetics , Proteins/genetics , Reproducibility of Results , STAT4 Transcription Factor/genetics , Sensitivity and SpecificityABSTRACT
Objective • To explore the value of stress hyperglycemia ratio (SHR) in predicting the prognosis of patients with acute myocardial infarction(AMI). Methods • A total of 434 patients diagnosed as having AMI were enrolled from October 2014 to October 2015. Immediate blood glucose, glycosylated hemoglobin (HbA1c) and SHR of each subjects were collected and calculated. Patients with and without diabetes were divided into several groups according to the occurrence of in-hospital and 2-year major adverse cardiovascular and cerebrovascular events (MACCEs). Indicators above were evaluated to predict the prognosis of patients with AMI. Results • Immediate blood glucose (P=0.003) and SHR (P=0.005) were significantly higher in MACCEs group than those in 2-year MACCEs-free group. Among AMI patients with diabetes mellitus, SHR in hospital MACCEs group was significantly higher than that in MACCEs-free group (P=0.001). Among AMI patients without diabetes, values of immediate blood glucose (P=0.001) and SHR (P=0.001) were higher in 2-year MACCEs group than those in MACCEs-free group. All-cause mortality was the highest (P=0.047, P=0.007) in the highest SHR group (three-digit relationship), no matter with or without diabetes mellitus. AMI patients with and without diabetes were further divided into two groups according to the median of SHR. High SHR could better predict in hospital MACCEs rate in AMI patients with diabetes as well as 2-year MACCEs rate without diabetes (P=0.023, P=0.000). Conclusion • Abnormal stress hyperglycemia is a risk factor of long-term poor prognosis in AMI patients. The value of SHR is more valuable in predicting the poor prognosis of AMI than immediate blood glucose, no matter the patients with or without diabetes.
